Marta Paoli

Marta Paoli

Auto-generated profile, based on publicly available information

Marta Paoli

University of Trento 2 Department of Cellular, Computational and Integrative Biology Trento, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
PMPaolo Manca
Paolo Manca
MPMarta Paoli
Marta Paoli
FGFrancesca Galardi
Francesca Galardi
FMFederica Morano
Federica Morano
SDSamantha Di Donato
Samantha Di Donato
FPFilippo Pietrantonio
Filippo Pietrantonio
Purpose: Longitudinal measuring of circulating tumor DNA (ctDNA) during systemic treatment of metastatic colorectal cancer (mCRC) is promising for disease monitoring, but it is hampered by high costs and lacks formal demonstration of clinical usefulness. Experimental Design: We leveraged METER, a novel, highly reproducible, computational workflow that infers ctDNA presence and fraction from low-pass whole-genome bisulfite sequencing to investigate baseline and 8-week ctDNA dynamics in patients with RAS wild-type mCRC undergoing first-line treatment with panitumumab/FOLFOX in the VALENTINO randomized phase II trial. IchorCNA was used to provide a benchmark for METER. Results: A total of 154 patients were evaluable. Baseline ctDNA was detected in 72.7% of patients and was associated with significantly higher risk of progression [1.65, 95% confidence interval (CI), 1.13–2.42; P = 0.010] and death (HR: 2.24; 95% CI, 1.37–3.66; P < 0.001). CtDNA clearance at 8 weeks was observed in 80.2% of patients with baseline detectable ctDNA; persistence of ctDNA was associated with significantly higher risk of progression (2.70, 95% CI, 1.63–4.49; P < 0.001) and death (HR: 3.37; 95% CI, 2–5.69; P < 0.001). CtDNA clearance was associated with a more profound depth of response (median −48.4% vs. −41.2%; P = 0.023) but not with a higher frequency of early tumor shrinkage (72% vs. 73.7%; P = 1). METER expanded the number of ctDNA-positive patients relative to copy-number alteration– and variant allele frequency–based methods. Conclusions: CtDNA detection and quantification with METER is a promising tool for cost-effective treatment monitoring in mCRC and can complement radiologic assessment of response dynamics.

11 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MPMarta Paoli
Marta Paoli
FGFrancesca Galardi
Francesca Galardi
ANAgostina Nardone
Agostina Nardone
CBChiara Biagioni
Chiara Biagioni
DRDario Romagnoli
Dario Romagnoli
MBMatteo Benelli
Matteo Benelli
The analysis of circulating tumor DNA (ctDNA) is increasingly used for monitoring disease in patients with metastatic cancer. Here, we introduce a robust and reproducible strategy combining low-pass whole methylome sequencing of plasma DNA with METER, a novel computational tool. Engaging prediction models trained on independent available datasets, METER enables the detection and quantification of tumor content (TC) and performs molecular cancer subtyping. Applied to plasma methylomes from early metastatic breast cancer patients, our method demonstrated reliable quantification, sensitive tumor detection below 3% of TC, and the ability to perform accurate Estrogen Receptor (ER) subtyping. METER provided clinically relevant predictions, underscored by associations with relevant prognostic factors, robust correlation with matched circulating tumor cells, and highly correlated with patients’ outcomes in challenging scenarios as TC<3%. Our strategy provides comprehensive and sensitive analysis of plasma samples, serving as a valuable yet cost-effective precision oncology tool.

16 September 2026 in iScience
Verified
Journal Article
Open access
ICIlaria Cherchi
Ilaria Cherchi
FOFrancesco Orlando
Francesco Orlando
OQOrsetta Quaini
Orsetta Quaini
MPMarta Paoli
Marta Paoli
YCYari Ciani
Yari Ciani
FDFrancesca Demichelis
Francesca Demichelis



21 December 2025 in bioRxiv
Verified
Preprint
Open access
ICIlaria Cherchi
Ilaria Cherchi
FOFrancesco Orlando
Francesco Orlando
OQOrsetta Quaini
Orsetta Quaini
MPMarta Paoli
Marta Paoli
YCYari Ciani
Yari Ciani
FDFrancesca Demichelis
Francesca Demichelis
The T2T-CHM13v2.0 reference genome added previously uncharacterized genomic sequences and improved the accuracy of repetitive stretches compared to former human genome assemblies. By comprehensive allelic variation analysis and read mapping statistics from sequencing reads aligned to hg38 and T2T-CHM13 assemblies in samples encompassing different sequencing designs and ethnicity groups, we observed that T2T-CHM13v2.0 assembly significantly reduces the reference mapping bias (RMB) and increases read mapping precision at clinically relevant sites, including BRCA1 pathogenic variants. Further, we report the presence of sequence dissimilarities among reference genomes in the proximity of ClinVar annotated variants, suggesting the need for data re-analysis and potential redesign of probes targeting clinically relevant regions. Overall, these findings support the implementation of T2T-CHM13 reference for the improvement of sequencing data analyses in the clinical genomic setting.